Cost-utility of new film-coated tablet formulation of deferasirox vs deferoxamine among major beta-thalassemia patients in Iran

OBJECTIVES: Thalassemia is a hereditary disease, which caused economic burden in developing countries. This study evaluated the cost utility of new formulation of deferasirox (Jadenu) vs deferoxamine (Desferal) among B-Thalassemia-major patients from payer perspective in Iran. METHODS: An economic-e...

Descripción completa

Detalles Bibliográficos
Autores principales: Saiyarsarai, Parisa, Khorasani, Elahe, Photogeraphy, Hasti, Ghaffari Darab, Mohsen, Seyedifar, Meysam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360196/
https://www.ncbi.nlm.nih.gov/pubmed/32664096
http://dx.doi.org/10.1097/MD.0000000000020949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360196/
https://www.ncbi.nlm.nih.gov/pubmed/32664096
http://dx.doi.org/10.1097/MD.0000000000020949

Ejemplares similares